Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Join Amber Hudgins, PharmD, a clinical pharmacist at Novant Health in Winston-Salem, North Carolina, presents an in-depth analysis of IL-23 inhibitors, as she discusses key findings from an ACR 2022 abstract comparing Guselkumab and Risankizumab in the treatment of psoriatic disease. This session is essential for rheumatology APPs, pharmacists, and clinicians aiming to refine their understanding of IL-23 inhibition and its impact on psoriasis and psoriatic arthritis management.

In this discussion, Amber explores the differences between Guselkumab and Risankizumab, detailing how their unique mechanisms of action influence therapeutic efficacy. She examines Guselkumab’s CD64 binding compared to Risankizumab’s mutated FC region and highlights how binding affinities may impact drug performance and patient outcomes. Insights from kinetic exclusion assays and flow cytometry provide a deeper understanding of immune cell interactions and the potential for Guselkumab’s CD64 binding to enhance durability and therapeutic response.

For clinicians looking to optimize treatment strategies in psoriatic disease, this comparative analysis provides valuable insights into IL-23 inhibitors and their evolving role in autoimmune therapy.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.